Abstract: Cervical cancer is preventable and curable in early stage. Different screening strategy should be chosen in different region and population. Cytology-based world-wide cervical cancer screening has led to a substantial reduction of the incidence of cervical cancer. However, the sensitivity of cytology for the detection of high-grade precursor lesions or cervical cancer is limited. After human papillomavirus （HPV） was identified as a cause of invasive cervical cancer, HPV DNA testing was developed to screen for the disease, screening strategies has changed（primary screening：cytology-based→HPV-based or Co-testing→HPV16/18 genotyping）. Although HPV testing is sensitive, it has poor specificity and positive predictive value, not everyone who carries HPV 16 or 18 develops CIN or cancer. This weakness could be overcome by application of biomarkers.

Key words: Uterine cervical neoplasms, Mass screening, Papillomaviridae, Biological markers